机构:[1]Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China临床科室内科中山大学肿瘤防治中心[2]Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Lymphoma, Beijing 100871, Peoples R China[3]Hop Haut Leveque, Dept Hematol, Ctr Francois Magendie, Pessac, France[4]Nagoya Daini Red Cross Hosp, Ctr Canc Chemotherapy, Dept Hematol & Oncol, Nagoya, Aichi, Japan[5]Osaka Univ, Grad Sch Med, Dept Clin Hematol & Diagnost, Osaka, Japan[6]Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol,Severance Hosp, Seoul, South Korea[7]Novartis Pharmaceut, Oncol Clin Dev, Florham Pk, NJ USA[8]Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland[9]Mayo Clin, Div Hematol, Rochester, MN USA
出处:
ISSN:
语种:
外文
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2012]版:
大类|1 区医学
小类|1 区肿瘤学
最新[2025]版:
大类|1 区医学
小类|1 区肿瘤学
第一作者:
第一作者机构:[1]Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China[2]Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Lymphoma, Beijing 100871, Peoples R China[3]Hop Haut Leveque, Dept Hematol, Ctr Francois Magendie, Pessac, France[4]Nagoya Daini Red Cross Hosp, Ctr Canc Chemotherapy, Dept Hematol & Oncol, Nagoya, Aichi, Japan[5]Osaka Univ, Grad Sch Med, Dept Clin Hematol & Diagnost, Osaka, Japan[6]Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol,Severance Hosp, Seoul, South Korea[7]Novartis Pharmaceut, Oncol Clin Dev, Florham Pk, NJ USA[8]Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland[9]Mayo Clin, Div Hematol, Rochester, MN USA
推荐引用方式(GB/T 7714):
Lin Tongyu,Zhu Jun,Bouabdallah Kamal,et al.PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).[J].JOURNAL OF CLINICAL ONCOLOGY.2012,30(15):-.
APA:
Lin, Tongyu,Zhu, Jun,Bouabdallah, Kamal,Ogura, Michinori,Hino, Masayuki...&Witzig, Thomas E..(2012).PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL)..JOURNAL OF CLINICAL ONCOLOGY,30,(15)
MLA:
Lin, Tongyu,et al."PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).".JOURNAL OF CLINICAL ONCOLOGY 30..15(2012):-